Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 30, 2007
Business Overview: The Company operates through two primary segments: CooperVision (CVI), which markets contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for gynecologists and obstetricians.
Key Financial Metrics
(In thousands, except per share data)
| Metric | Three Months Ended Apr 30, 2007 |
Three Months Ended Apr 30, 2006 |
Six Months Ended Apr 30, 2007 |
Six Months Ended Apr 30, 2006 |
|---|---|---|---|---|
| Net Sales | $225,535 | $211,397 | $444,955 | $417,136 |
| Gross Profit | $126,456 | $131,363 | $256,368 | $260,524 |
| Gross Margin % | 56% | 62% | 58% | 62% |
| Operating Income | $10,531 | $24,480 | $26,293 | $58,194 |
| Net (Loss) Income | $(527) | $13,701 | $4,821 | $31,655 |
| Diluted EPS | $(0.01) | $0.30 | $0.11 | $0.69 |
| Cash from Operations (6mo) | $48,434 (2007) vs $76,364 (2006) | |||
| Total Debt | $865.9 million (Apr 30, 2007) | |||
| Cash & Equivalents | $12.0 million (Apr 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% year-over-year for both the three and six-month periods. Growth was driven by CSI (up 26% and 22% respectively) and CVI (up 4% for both periods).
- Profitability Decline: Operating income decreased 57% for the quarter and 55% for the six-month period. Net income dropped significantly, resulting in a net loss for the quarter.
- Margin Compression: Gross margin declined from 62% to 56% (quarter) and 62% to 58% (six months). This was attributed to manufacturing inefficiencies related to new silicone hydrogel products, integration costs, and a shift to lower-margin sphere products.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 14% (quarter) and 15% (six months) due to integration costs, distribution rationalization, and litigation expenses. Restructuring costs increased significantly, totaling $4.7 million for the six months ended April 30, 2007.
- Debt Refinancing: In January 2007, the Company refinanced its credit facility, issuing $350 million in Senior Notes and establishing a $650 million Revolver. Total debt increased to $865.9 million.
Guidance, Outlook, and Risks
- Product Outlook: The Company is ramping up production of silicone hydrogel lenses, with an expanded U.S. launch planned for late June 2007. Management expects manufacturing inefficiencies and start-up costs to continue throughout the fiscal year.
- Capital Expenditures: Expected to be approximately $160 million for fiscal 2007, focused on expanding manufacturing capacity and consolidating distribution centers.
- Legal Proceedings:
- Securities Litigation: A consolidated class action lawsuit alleges improper accounting for the Ocular merger and inflated earnings guidance. A hearing on the motion to dismiss is scheduled for July 16, 2007.
- Patent Litigation: Ongoing lawsuits with CIBA Vision regarding silicone hydrogel patents and with Bausch & Lomb regarding toric lens patents.
- Tax Litigation: A U.S. Tax Court decision reduced a deficiency related to Ocular Sciences to $3.5 million; however, Ocular returns for 2002-2005 remain under IRS examination.
- Management Transition: CEO A. Thomas Bender intends to relinquish his role by the end of 2007. The Board is conducting a succession search.
- Market Risks: Risks include the impact of contact lens solution recalls on consumer confidence, foreign currency fluctuations, and interest rate changes on variable debt.
Investor Verification Checklist
- Restructuring Costs: Verify the total estimated cost of the Ocular integration plan ($45-$50 million) and the remaining cash outlays required.
- Silicone Hydrogel Ramp-up: Monitor the success of the expanded U.S. launch in late June 2007 and the timeline for achieving manufacturing efficiency targets.
- Legal Exposure: Track the status of the securities class action lawsuit and the outcome of the motion to dismiss scheduled for July 2007.
- Debt Covenants: Confirm continued compliance with the Interest Coverage Ratio (currently 6.33:1) and Total Leverage Ratio (currently 3.63:1) under the new credit facility.
- CEO Succession: Monitor the progress of the CEO search and the potential impact of leadership transition on strategic execution.